Phagos

Market position

Phagos is described in trade press as one of Europe's most advanced players in precision bacteriophage therapeutics and as the first company authorized to market personalized phage-based veterinary drugs. Coverage positions it against a background of AMR, which the WHO and cited estimates link to roughly 39 million projected deaths globally over 25 years, and notes that one in three antibiotics used in livestock is now reported to be ineffective.

Sources contrast Phagos with companies that produce static phage formulations, to which bacteria can develop resistance, or that rely on laborious lab testing; Phagos instead offers personalized, continuously updated therapies designed computationally. Additional stated differentiators are its first-of-its-kind regulatory authorization for personalized phage-based veterinary drugs and its filed patents on the AI platform.

Technology

The Alphagos platform analyzes the full genomes of both phages and bacteria and uses AI to predict phage-bacteria interactions, simulating large numbers of interactions computationally in order to select effective phage combinations rather than relying on laboratory trial-and-error. The company says custom treatments can be designed in minutes rather than years and delivered in two months for veterinary use, and that treatments are continuously updated using field data. Phagos has filed patents covering its AI technology. A 2025 hackathon it co-organized with AWS focused on applying large language models to phage genomes using Amazon SageMaker.

Go-to-market

The company entered the market through animal health, citing shorter R&D and regulatory cycles and clear demand from veterinarians and farmers seeking antibiotic-free solutions. It has run pilot deployments with industry partners across multiple continents and cites its French regulatory authorization as a 'proven regulatory model' for expansion into Europe, the Americas and Asia. It has also organized developer-facing events, such as a hackathon co-organized with Amazon Web Services in May 2025, as a recruiting and community channel.

Livestock producers and veterinarians in the chicken, cattle, swine and shrimp sectors; the company states a longer-term intent to address human health and crop health.

Geography

Headquartered in the Paris area of France, with offices cited at DocCity, 5 Rue Gardenat Lapostol, Suresnes; one aggregator lists the HQ as Suresnes, Ile-de-France. Deployments span three continents, and Series A proceeds are earmarked for expansion across Europe, Asia and the Americas.

History

Founded in 2021 (an internal record lists 2022), Phagos raised an early round reported by one aggregator as a $2M seed in September 2022 with Hoxton Ventures. In May 2025 it co-organized a two-day AI-and-biology hackathon with AWS at its Suresnes offices. In October 2025 it announced a €25 million (~$30 million) Series A co-led by CapAgro, Hoxton Ventures, CapHorn and Demeter, alongside news that it had become the first company authorized to market personalized phage-based veterinary drugs.

Risks & controversies

Sources note that adoption of phage therapy has historically faced skepticism from regulators and practitioners due to limited familiarity, cost concerns, and entrenched reliance on antibiotics, and that scalability has been constrained by the diversity of bacterial strains and the number of potential phage-bacteria interactions. Reported figures vary across sources: founding year is given as 2021 in press coverage versus 2022 internally; one aggregator reports $31.0M total raised across two rounds and lists a partly different investor set from the primary press coverage. AgFunderNews discloses that its parent company AgFunder is an investor in Phagos.